Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorundrostat (Primary)
  • Indications Hypertension; Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE-HTN
  • Sponsors Mineralys Therapeutics

Most Recent Events

  • 14 Jun 2026 According to a Mineralys Therapeutics media release, the post hoc analysis of circulating proteomic data from Launch-HTN and Advance-HTN trials was presented in a late-breaking poster presentation at ENDO 2026, the Endocrine Society's annual meeting.
  • 23 Apr 2025 According to a Mineralys Therapeutics media release,the New England Journal of Medicine (NEJM) published the detailed results from the \pivotal Phase 2 Advance-HTN trial,
  • 23 Apr 2025 Results presented in a Mineralys Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top